Literature DB >> 10331082

Inhibition of nitric oxide synthase as a potential therapeutic target.

A J Hobbs1, A Higgs, S Moncada.   

Abstract

Nitric oxide (NO) regulates numerous physiological processes, including neurotransmission, smooth muscle contractility, platelet reactivity, and the cytotoxic activity of immune cells. Because of the ubiquitous nature of NO, inappropriate release of this mediator has been linked to the pathogenesis of a number of disease states. This provides the rationale for the design of therapies that modulate NO concentrations selectively. A well-characterized family of compounds are the inhibitors of NO synthase, the enzyme responsible for the generation of NO; such agents are potentially beneficial in the treatment of conditions associated with an overproduction of NO, including septic shock, neurodegenerative disorders, and inflammation. This article provides an overview of NO synthase inhibitors, focusing on agents that prevent binding of substrate L-arginine.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10331082     DOI: 10.1146/annurev.pharmtox.39.1.191

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  101 in total

Review 1.  NO as a signalling molecule in the nervous system.

Authors:  Juan V Esplugues
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

Review 2.  The nitric oxide pathway in the cardiovascular system.

Authors:  S Llorens; J Jordán; E Nava
Journal:  J Physiol Biochem       Date:  2002-09       Impact factor: 4.158

3.  Intracellular formation of "undisruptable" dimers of inducible nitric oxide synthase.

Authors:  Pawel J Kolodziejski; Mohammad B Rashid; N Tony Eissa
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-12       Impact factor: 11.205

4.  Phenyl Ether- and Aniline-Containing 2-Aminoquinolines as Potent and Selective Inhibitors of Neuronal Nitric Oxide Synthase.

Authors:  Maris A Cinelli; Huiying Li; Anthony V Pensa; Soosung Kang; Linda J Roman; Pavel Martásek; Thomas L Poulos; Richard B Silverman
Journal:  J Med Chem       Date:  2015-10-27       Impact factor: 7.446

5.  Nitric oxide activation of guanylyl cyclase in cells revisited.

Authors:  Brijesh Roy; John Garthwaite
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-01       Impact factor: 11.205

Review 6.  Comparative folate metabolism in humans and malaria parasites (part II): activities as yet untargeted or specific to Plasmodium.

Authors:  Alexis Nzila; Steve A Ward; Kevin Marsh; Paul F G Sims; John E Hyde
Journal:  Trends Parasitol       Date:  2005-07

7.  Apigenin inhibits PMA-induced expression of pro-inflammatory cytokines and AP-1 factors in A549 cells.

Authors:  Rajeshwari H Patil; R L Babu; M Naveen Kumar; K M Kiran Kumar; Shubha M Hegde; Govindarajan T Ramesh; S Chidananda Sharma
Journal:  Mol Cell Biochem       Date:  2015-02-10       Impact factor: 3.396

8.  L-arginine and Alzheimer's disease.

Authors:  Jing Yi; Laura L Horky; Avi L Friedlich; Ying Shi; Jack T Rogers; Xudong Huang
Journal:  Int J Clin Exp Pathol       Date:  2008-10-02

9.  Potent and selective neuronal nitric oxide synthase inhibitors with improved cellular permeability.

Authors:  Fengtian Xue; Jianguo Fang; William W Lewis; Pavel Martásek; Linda J Roman; Richard B Silverman
Journal:  Bioorg Med Chem Lett       Date:  2009-11-22       Impact factor: 2.823

10.  Ubiquitination of inducible nitric oxide synthase is required for its degradation.

Authors:  Pawel J Kolodziejski; Aleksandra Musial; Ja-Seok Koo; N Tony Eissa
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.